Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Vanderweele

Medical Oncology Chicago, IL Medical Doctor

NPI 1689846834 CMS profile 581903

676 N Saint Clair St Ste 850, Chicago, IL 60611

Open in the dashboard

General payments

$30,351

48 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,097,307 paid to institutions, not to them · program years 2019–2025

Through program year 2025, David Vanderweele of Chicago, IL is reported in the CMS Open Payments database as having received $30,351 across 48 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,097,307 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 77th percentile of Medical Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $9,645 14
2023 General $4,937 7
2022 General $8,426 10
2021 General $5,345 10
2020 General $1,591 3
2019 General $407 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Vanderweele
  • Medical Oncology median
  • Middle half of Medical Oncology
  • National median

In program year 2025, general payments to David Vanderweele were reported at $9,645. Among 3,316 Medical Oncology profiles paid that year, the median was $1,128 and the middle half received between $147 and $5,675.

Show as a table
Year David Vanderweele Medical Oncology median Middle half National median
2019 $407 $968 $140–$6,658 $163
2020 $1,591 $747 $102–$5,891 $114
2021 $5,345 $430 $50–$4,098 $132
2022 $8,426 $812 $127–$4,907 $149
2023 $4,937 $957 $144–$5,248 $160
2024 $0 $1,042 $149–$5,650 $164
2025 $9,645 $1,128 $147–$5,675 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Bayer HealthCare Pharmaceuticals Inc. $20,572 27 payments
  2. Exelixis Inc. $5,452 11 payments
  3. Pfizer Inc. $2,205 2 payments
  4. Clovis Oncology, Inc. $1,500 1 payment
  5. Genzyme Corporation $407 4 payments
  6. AstraZeneca Pharmaceuticals LP $124 1 payment
  7. Genentech, Inc. $91 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $22,320 6 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,960 1 payment
  3. Travel and Lodging $2,489 16 payments
  4. Food and Beverage $1,583 25 payments
Products named General payments · program years 2019–2025
  1. Xofigo $17,737 21 payments
  2. Nubeqa $15,831 20 payments
  3. CABOMETYX Oncology $5,345 10 payments
  4. XTANDI $2,070 1 payment
  5. Rubraca $1,500 1 payment
  6. NO PRODUCT DISCUSSED $407 4 payments
  7. LYNPARZA $124 1 payment
  8. CABOMETYX Oncology $107 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

789

Median for Medical Oncology: 414

Drug cost

$3,206,257

Median for Medical Oncology: $849,427

Branded share of claims

42%

Median for Medical Oncology: 28.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nubeqa Darolutamide Brand 74 $914,688
Cabometyx Cabozantinib S-Malate Brand 36 $745,069
Xtandi Enzalutamide Brand 44 $563,360
Orgovyx Relugolix Brand 162 $430,395
Abiraterone Acetate Generic 161 $332,925
Inlyta Axitinib Brand 15 $217,778
Tamsulosin Hcl Generic 28 $862
Prednisone Generic 200 $804
Prochlorperazine Maleate Generic 16 $134
Dexamethasone Generic 14 $118

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,431 Part D prescribers listed as Medical Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 129 billing codes

Paid by Medicare

$1,765,136

Of which drugs: $1,593,508

Medicare patients

537

Average age 75

Services billed

79,008

123 women, 414 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Cancer 71%
High blood pressure 70%
Arthritis 39%
Ischemic heart disease 32%
Chronic kidney disease 28%
Diabetes 24%
Atrial fibrillation 19%
Osteoporosis 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, daratumumab, 10 mg and hyaluronidase-fihj J9144 Office 33 9,360 $365,170
Injection, denosumab, 1 mg J0897 Office 46 9,300 $192,801
Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg J1569 Office 40 3,020 $107,263
Injection, teclistamab-cqyv, 0.5 mg J9380 Office 11 4,284 $105,239
Leuprolide acetate (for depot suspension), 7.5 mg J9217 Office 86 672 $93,931
Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg Q5107 Office 12 800 $16,491
Injection, pegfilgrastim, excludes biosimilar, 0.5 mg J2506 Office 12 156 $10,467
Injection, bortezomib (velcade), 0.1 mg J9041 Office 33 1,715 $2,413
Injection, methylprednisolone sodium succinate, 5 mg J2919 Office 31 3,874 $864
Injection, irinotecan, 20 mg J9206 Office 17 339 $688

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

48 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Medical Oncology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record